Mosbrooker Eric 4
4 · Avidity Biosciences, Inc. · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
Avidity (RNAM) CCO Eric Mosbrooker Sells 306,601 Shares
What Happened
Eric Mosbrooker, Chief Commercial Officer of Avidity Biosciences (RNAM), disposed of a total of 306,601 company securities on Feb 27, 2026 in connection with the company’s merger with Novartis. The filing shows: 79,413 shares of common stock were transferred to the issuer (treated under the merger) and 227,188 derivative instruments (listed as two derivative dispositions of 177,188 and 50,000) were disposed. The merger consideration specified in the Merger Agreement is $72.00 per share; the 79,413 common shares therefore represent approximately $5.72 million of value. The derivative instruments (options) were cashed out per the merger terms (see footnote) for a cash payment equal to the excess of $72.00 over each option’s exercise price — the filing does not list the cash amounts for the options.
Key Details
- Transaction date: February 27, 2026 (filed Feb 27, 2026). Transaction code: D (Disposition to issuer) for all items.
- Shares disposed: 79,413 common shares; 177,188 derivative instruments; 50,000 derivative instruments — total 306,601 underlying shares.
- Price / value: common stock subject to merger consideration of $72.00/share (~$5,717,736 for 79,413 shares). Options/derivatives were settled for cash equal to (72.00 − exercise price) × number of options; specific cash amounts for options not reported in the Form 4. The Form shows price as N/A for the reported dispositions.
- Footnotes: F1 — common shares (including shares issuable upon previously reported RSUs) were disposed under the Agreement and Plan of Merger dated Oct 25, 2025. F2 — reported options were cashed out under the Merger Agreement for the excess of $72 over the exercise price.
- Shares owned after the transaction: not provided in the information you supplied (not reported here).
- Timeliness: filing date matches the report period date (Feb 27, 2026); filing appears to be timely.
Context
- These dispositions are part of the company’s merger with Novartis and reflect cash/merger settlement terms rather than open-market selling by the insider. For the options, this was a cash-out settlement (not a cashless exercise to hold shares).
- Such merger-related dispositions are routine in acquisitions and do not necessarily signal the insider’s view on the company’s long-term prospects.
Insider Transaction Report
- Disposition to Issuer
Common Stock
[F1]2026-02-27−79,413→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
[F2]2026-02-27−177,188→ 0 totalExercise: $9.05Exp: 2033-12-31→ Common Stock (177,188 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
[F2]2026-02-27−50,000→ 0 totalExercise: $31.42Exp: 2035-01-05→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
- [F2]The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.